A Clinical Trial Is Not a Telehealth Company Performance Report

A weight-loss percentage can make a telehealth offer look more thoroughly tested than it is. A reader sees a medication name, a clinical-trial result and a convenient enrollment button, then reasonably wonders whether the advertised service delivers that result. But a study of a specific medicine does not measure a company’s prescribing decisions, pharmacy fulfillment, follow-up or patient outcomes. Those require their own evidence, even when the company offers the same named product studied in a trial.

Public documentation from CoreAge Rx, Ro, Enhance.MD, Sesame, Walgreens and Found illustrates the distinction. Their consulted pages describe genuine service features, prices and responsibilities, but those descriptions are not interchangeable with measured clinical performance. This guide separates what trials establish, what providers document and what remains unanswered. Sources were consulted October 19, 2026; that is a research date, not a claim that every page was updated then.

At a glance

Trial evidence has boundaries: STEP 1 studied a specific subcutaneous semaglutide regimen for 68 weeks, not a telehealth company, compounded preparation or microdosing program.
Sources: [3]
Product approval is not provider approval: Compounded preparations are not FDA approved. FDA recommends them when an individual’s medical needs cannot be met by an approved drug.
Sources: [1]
Membership is not medication: Ro documents that its Body membership includes clinical and support services but excludes medication costs.
Sources: [6]
Quality claims need attribution: Found says its compounded semaglutide undergoes third-party potency, purity and sterility testing; the consulted documentation does not identify the laboratory or provide certificates.
Sources: [18]
Support channels are not equivalent: Walgreens advertises 24/7 pharmacy-expert chat, while Weight Management follow-up chat visits and additional video visits cost $49 each.
Sources: [27] [19]

Start by identifying what the claim actually measures

Evidence becomes easier to evaluate when the question is narrow. “Does this medicine produce weight loss under study conditions?” differs from “Does this company reliably provide the advertised care?” A third question concerns the preparation dispensed: what formulation, route and presentation will the patient receive? A persuasive answer to one does not automatically answer the others. Our guide to what public provider documents can prove explains why a written service promise remains different from a measured outcome.

Consider Ro’s disclosure that members were paid for testimonials. That disclosure supplies useful advertising context, but the stories do not establish a representative outcome rate. Likewise, CoreAge Rx’s advertised approximately 24-hour medical feedback and Ro’s eligibility decision within two days describe access targets, not weight-loss effectiveness. They also do not measure prescription approval rates, successful delivery or sustained engagement. Ask what event was counted before interpreting any number as evidence of company performance.

Match the claim to the evidence it needs
Claim type	What the cited material can show	What it does not establish
Randomized drug trial	Outcomes for the studied product and population	A telehealth company’s outcomes
Provider service description	The advertised process or included services	How consistently the promise is fulfilled
Patient testimonial	An individual’s presented experience	A representative success or adverse-event rate
Pharmacy testing claim	The provider’s stated quality-control process	Clinical equivalence or verified batch results
Starting price	An advertised conditional entry point	The complete ongoing treatment bill

Sources: [29] [14]

Read the trial before borrowing its percentage

STEP 1 was a double-blind randomized trial involving 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Both groups received lifestyle intervention. At 68 weeks, mean weight change was −14.9% with studied subcutaneous semaglutide 2.4 mg weekly versus −2.4% with placebo. Gastrointestinal events led to discontinuation in 4.5% and 0.8%, respectively. Novo Nordisk funded the trial. The dose identifies the study arm, not instructions for a reader.

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes, for 72 weeks. Mean changes with studied subcutaneous tirzepatide 5, 10 and 15 mg weekly were −15.0%, −19.5% and −20.9%, versus −3.1% with placebo. Gastrointestinal events were most common; adverse-event discontinuation was 4.3%, 7.1% and 6.2%, versus 2.6%. Eli Lilly funded it. Read SURMOUNT-1 without making a provider ranking: neither trial measures these companies, and comparing their percentages is not a randomized head-to-head comparison.

Sources: [3] [4]

Check whether the offered preparation matches the studied one

An ingredient name is not a complete product description. CoreAge Rx says its compounded tirzepatide typically includes B-12; a formulation without it requires discussion during intake and provider assessment. It also markets separate semaglutide and tirzepatide “Microdosing Therapy” offerings. Enhance.MD markets Elite as an injectable combination of semaglutide and tirzepatide. These are documented offerings, not evidence that trial results transfer to vitamin blends, microdoses or combination preparations. Commercial descriptions of metabolic support do not resolve that gap.

FDA approval applies to a specific product, not the platform arranging care. Compounded preparations lack FDA premarket review for safety, effectiveness and quality; that alone does not prove clinical inequivalence. FDA recommends compounded drugs when an individual’s needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. The distinction between approved medicines and compounded preparations therefore requires more precision than either “the same ingredient” or “not approved” supplies on its own.

Sources: [14] [15] [16] [33] [1]

Separate organizational claims from verified clinical responsibility

A familiar company name may cover several organizations. CoreAge Rx identifies DSO Fine Shrimp as the technology and administrative coordinator, while assigning evaluations, treatment planning and prescribing exclusively to three independently operated professional entities. Enhance.MD similarly describes an administrative platform rather than a medical or pharmacy practice. Its FAQ says clinicians include physicians and nurse practitioners. These disclosures help identify responsibility, but this research did not independently verify professional licenses, employment arrangements or the quality of clinical decisions.

Walgreens’ terms assign clinical control to independent medical practices rather than Walgreens Health Services LLC. Sesame likewise says affiliated practices are independently owned and operated by licensed clinicians, and its terms state that Sesame is not a pharmacy. A useful question is therefore not simply whether a brand is reputable, but which practice treats the patient, which clinician makes decisions and which pharmacy dispenses the medicine. A trial publication cannot supply those company-specific answers.

Sources: [20] [12] [13] [11] [9] [10]

Treat follow-up descriptions as service evidence, not outcome evidence

Some providers describe follow-up more concretely than others. Found says its team follows patients receiving compounded tirzepatide monthly. It describes insured care as synchronous video visits, including before each refill, while cash-pay care is text-based in most cases. Enhance.MD’s Core subscription documents ongoing care and metabolic testing every six months. These differences matter when preparing questions about access, but they do not establish which service produces better clinical outcomes or more consistently completes its stated follow-up.

Availability language also needs careful reading. CoreAge Rx’s “24/7 Provider Support” heading is developed with text about round-the-clock customer support, not a demonstrated physician response commitment. Ro advertises unlimited provider messaging and regular check-ins without specifying a response deadline. Found’s 24/7 Aimee access refers to an AI companion, not continuous human care. NIDDK describes follow-up as attention to tolerance and response; a messaging feature or renewal notice alone does not demonstrate that this clinical work occurred.

Sources: [5] [31] [8] [24] [29] [28] [2]

Ask what supports pharmacy and delivery promises

Found says its compounded semaglutide receives third-party potency, purity and sterility testing before shipment. That is a provider-attributed quality claim; the consulted documentation does not name the testing laboratory or supply certificates. Enhance.MD names pharmacy partners, but the FAQ and terms list different networks. CoreAge Rx’s FAQ requires affiliated-network fulfillment, while its terms allow requesting another pharmacy before ordering. These discrepancies call for product-specific clarification, not assumptions about which pharmacy will handle a particular prescription.

Delivery claims have similarly limited meanings. Ro says cash-pay prescriptions sent to its own or partner pharmacies ship within a week after prescribing; that is dispatch, not arrival. CoreAge Rx separately estimates approximately five to seven business days for order completion when documentation is submitted promptly and approximately two to three business days after pharmacy shipment for arrival. Neither establishes a guaranteed purchase-to-door interval. FDA explicitly advises not using an injectable GLP-1 that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy.

Sources: [18] [13] [23] [14] [22] [26] [7] [1]

Use billing documents to test the completeness of the offer

Price documentation tests transparency, not drug effectiveness. Ro advertises Body membership at $39 for the first month, then $149 monthly on the monthly plan, or as low as $74 per month with annual prepayment; medication is separate. Sesame advertises subscription pricing starting at $59 per month with an annual subscription, excluding medication, while clinicians can charge more. Its $99 month-to-month option is described elsewhere as billed every 28 days. Four weeks and a calendar month are not interchangeable.

Refund language deserves the same scrutiny as outcome language. CoreAge Rx’s FAQ promises a full automatic refund if a prescription is not approved, but its policy retains an applicable $50–$100 consultation fee. Sesame’s program page describes cancellation before the next cycle, while general terms require email or telephone notice at least 48 hours before renewal processing. Neither cancellation nor a favorable drug study establishes a refund entitlement. Preserve the checkout terms and request clarification when public pages disagree.

Sources: [6] [30] [14] [7] [10]

What a company performance report would need to disclose

To substantiate a company-level outcome claim, readers would need more than selected success stories: a defined patient population, the treatment actually received, an observation period and an explanation of missing follow-up. A report should distinguish everyone enrolled from those prescribed medication and those still participating when outcomes were measured. None of the clinical trials discussed here supplies that provider-specific information. A service feature can be valuable without proving superior weight loss, and absent outcome documentation does not prove poor care.

Safety comparisons require equal restraint. FDA adverse-event reports lack a denominator for calculating rates and do not automatically establish causation; they are not a reviewed company’s event rate. Conversely, a provider’s safety language does not demonstrate absence of harm. Use a checklist for GLP-1 medical claims to record the precise claim, its source, the population studied and the remaining gap. This produces a more useful comparison than borrowing a trial percentage for a company leaderboard.

Sources: [3] [4] [1]

Questions & answers

Does CoreAge Rx’s B-12 formulation inherit tirzepatide trial results?

No. CoreAge Rx documents that its compounded tirzepatide typically contains B-12. SURMOUNT-1 was not a study of that provider or its blend. Ask for the exact prescribed formulation and the evidence supporting claims about it; the shared ingredient name does not close the evidence gap.

Sources: [14] [4]

Does Ro’s insurance checker establish treatment eligibility?

No. Ro says the checker collects coverage information and does not request treatment or issue prescriptions. Clinical eligibility requires provider review. Its insurance coordination currently covers selected products, and insurance does not cover the Body membership fee.

Sources: [25] [17] [26]

Does Enhance.MD’s Elite description establish superiority?

No. Elite is marketed as an injectable semaglutide-and-tirzepatide combination. Neither STEP 1 nor SURMOUNT-1 tested that offering. Its commercial positioning for people who have plateaued should not be treated as a measured superiority finding or an individual treatment recommendation.

Sources: [33] [3] [4]

Does Sesame’s subscription include all laboratory costs?

No. Included testing is limited to Quest Diagnostics, excluding facilities in AZ, HI, ND, NJ, NY, OK, RI, SD and WY. In those states, laboratory fees are additional. A description of included testing therefore needs its geographic conditions, not just the headline benefit.

Sources: [30]

Is Walgreens’ 24/7 pharmacy chat the same as ongoing prescriber care?

No. Walgreens distinguishes pharmacy-expert chat from Weight Management visits. Pharmacy chat may involve waiting and is not for emergencies. Initial clinical visits start at $49; follow-up chat visits and additional video visits are $49 each, with medication separate. Chat availability does not establish a zero fee.

Sources: [27] [19]

Does Found’s “with insurance” compounded price mean insurance covers the drug?

No. Found’s billing consent makes patients responsible for compounded GLP-1 charges and prohibits submitting those amounts to insurance. Its pricing explanation ties the insurance rate to clinical-care coverage, with possible copays, coinsurance and deductibles. The subscription is also described as a noncovered service.

Sources: [32] [21]

Our assessment

Clinical trials can support carefully bounded statements about studied medicines. Provider documentation can explain access, responsibilities, charges and advertised support. Both are useful, but neither substitutes for measured company outcomes. These providers document meaningful differences in care delivery, while leaving important questions about implementation and performance unanswered. A practical comparison starts with the exact product and service terms, identifies who is responsible, and labels commercial claims as claims. Missing outcome evidence is not proof of poor care; a strong drug study is not proof of excellent service.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

A Clinical Trial Is Not a Telehealth Company Performance Report

At a glance

01Start by identifying what the claim actually measures

02Read the trial before borrowing its percentage

03Check whether the offered preparation matches the studied one

04Separate organizational claims from verified clinical responsibility

05Treat follow-up descriptions as service evidence, not outcome evidence

06Ask what supports pharmacy and delivery promises

07Use billing documents to test the completeness of the offer

08What a company performance report would need to disclose